FDA clearance of IND for first-in-class ILP100-Topical immunotherapy treatment of surgical wounds in patients with prediabetes, diabetes and obesity
News
Ilya Pharma makes strategic investment in bioanalytical company
Ilya Pharma has made a strategic investment in its supply chain to facilitate development of its ILP pipeline by acquiring one of its long-term partners, Nordic Bioanalysis.
8.5 MEUR to advance our three programs
Ilya Pharma has closed a 8.5 million EUR funding round where the EIC Fund participated and was joined by an international consortium of family offices and private investors
Scientific abstract of ILP100-Oral in two colitis models selected for poster at Experimental Biology Philadelphia April 4 2022
Experimental Biology (EB) is the annual meeting of five societies that explores the latest research in anatomy, biochemistry and molecular biology, investigative pathology, pharmacology, and physiology. Participants represent scientists from academic institutions, government agencies, nonprofit organizations and industry.
Ilya Pharma presenting at Hybrid event BIO CEO Investor conference in NYC 14-17 February 2022
Open position as CMC project manager
Ilya Pharma invited to attend the 40th JP Morgan Health Care Conference 10-13 January, 2022
Largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.